<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065490</url>
  </required_header>
  <id_info>
    <org_study_id>CSP005</org_study_id>
    <nct_id>NCT04065490</nct_id>
  </id_info>
  <brief_title>Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)</brief_title>
  <official_title>A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects With Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiThera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiThera, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective
      multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry
      AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a double-masked, sham-controlled, parallel design prospective, multi-site study
      on the use of photobiomodulation (PBM) as a treatment for visual impairment in subjects with
      dry AMD. Subjects will receive repeated sham or PBM treatments at several time-points
      throughout the 2-year study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Valeda Light Delivery System</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>21 months</time_frame>
    <description>Mean change from baseline in BCVA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>21 months</time_frame>
    <description>Mean change from baseline (pre-treatment) in contrast sensitivity at 40 cm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Drusen Volume</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline (pre-treatment) in central Drusen volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Drusen Thickness</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline (pre-treatment) in central Drusen thickness.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Contrast Sensitivity</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline (pre-treatment) in contrast sensitivity at 80 cm and 120 cm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Function Questionnaire</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline (pre-treatment) in Visual Function Questionnaire (VFQ-25) composite score.</description>
  </other_outcome>
  <other_outcome>
    <measure>Reading Speed</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline (pre-treatment) to Month 21 in monocular reading speed assessed by the Radner Reading Chart.</description>
  </other_outcome>
  <other_outcome>
    <measure>Geographic Atrophy</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline in the GA lesion area of the PBM treatment group versus the sham treatment group, as measured by FAF.</description>
  </other_outcome>
  <other_outcome>
    <measure>Low Luminance- Best Corrected Visual Acuity</measure>
    <time_frame>21 Months</time_frame>
    <description>Mean change from baseline in the LLBVCA.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Dry Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>PBM Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Valeda™ Light Delivery System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Treatment</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The Valeda™ Light Delivery System non-effective treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Valeda PBM treatment</intervention_name>
    <description>The Valeda Light Delivery System</description>
    <arm_group_label>PBM Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Valeda Sham treatment</intervention_name>
    <description>The sham mode of the Valeda Light Delivery System.</description>
    <arm_group_label>Sham Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female at least 50 years of age at Screening visit

          2. ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to
             20/32). *If the subject meets this criterion at the Screening Visit, but the Baseline
             BCVA letter score is between 48 and 77, the subject may be entered in the study.

          3. Diagnosis of dry AMD as defined by the presence of the following:

             Drusen that are intermediate in size or larger (63 μm or larger in diameter) with at
             least a few (3) being regular drusen and not pseudodrusen and/or geographic atrophy
             (GA) visible on two of the following: color fundus images, OCT and/or FAF, to be
             confirmed by the reading center

          4. Able to communicate well with the Investigator and able to understand and comply with
             the requirements of the study

          5. Informed of the nature of this study and has provided written, informed consent in
             accordance with institutional, local and national regulatory guidelines

        Exclusion Criteria:

          1. Current or history of neovascular maculopathy that includes any of the following (to
             be confirmed by the reading center):

               1. Choroidal neovascularization (CNV) defined as pathologic angiogenesis originating
                  from the choroidal vasculature that extends through a defect in Bruch's membrane

               2. Serous and/or hemorrhagic detachment of the neurosensory retina or retinal
                  pigment epithelial (RPE)

               3. Retinal hard exudates (a secondary phenomenon resulting from chronic
                  intravascular leakage)

               4. Subretinal and sub-RPE fibrovascular proliferation

               5. Disciform scar (subretinal fibrosis)

          2. Presence of center involving GA within the central ETDRS 1 mm diameter at Screening,
             to be confirmed by the reading center

          3. Media opacities, including cataracts, which might interfere with visual acuity or
             imaging in the study eye(s). Subjects should not be entered if there is likelihood
             that they will require cataract surgery in the study eye in the next 24 months.

          4. Posterior capsule opacification, which might interfere with visual acuity or imaging
             in the study eye(s). Subjects should not be entered if there is likelihood that they
             will require surgery in the study eye in the next 24 months.

          5. Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3
             months prior to Screening

          6. Ocular disorder or disease that partially or completely obstructs the pupil (e.g.
             posterior synechia in uveitis)

          7. Visually significant disease in any ocular structure apart from dry AMD (e.g. diabetic
             macular edema, glaucoma (using &gt;2 eye drop medications, uncontrolled IOP and/or
             central/paracentral visual field loss), glaucoma surgery, active uveitis, active
             vitreous disease, intraocular tumor, retinal vascular diseases)

          8. Ocular disorder or disease other than dry AMD that could cause drusen
             (glomerulonephritis Type 2, Autosomal dominant drusen), GA (North Carolina dystrophy)
             or mitochondrial diseases (parafoveal petaloid GA, Stargardt disease)

          9. Presence or history of disease or condition affecting functional vision without
             obvious structural abnormalities (e.g. amblyopia, stroke, nystagmus)

         10. Serious medical illness that will prevent the subject from performing study activities
             (including cardiac, hepatic, renal, respiratory, endocrinologic, neurologic, or
             hematologic disease) or, in the judgement of the Investigator, is likely to require
             surgical intervention or hospitalization at any point during the study

         11. Presence of or history of malignancy within the past 5 years other than non-melanoma
             skin or squamous cell cancer or cervical carcinoma in-situ

         12. Is non-ambulatory

         13. Presence or history of known light sensitivity to yellow light, red light, or near
             infrared radiation (NIR), or if they have a history of light activated CNS disorders
             (e.g. epilepsy, migraine)

         14. Use of any photosensitizing agent (e.g. topicals, injectables, oral) within 30 days of
             treatment without consulting subject's physician

         15. History of drug, alcohol or substance abuse within 3 months prior to Screening

         16. Has received an investigational drug or treatment with an investigational device
             within 3 months prior to Screening

         17. If on any anti-oxidant or vitamin Age-Related Eye Disease Study (AREDS) supplement for
             dry AMD, has not been stabilized for a minimum of 1 month prior to Screening. Subjects
             are considered to be stable if they are taking the AREDS supplements consistently as
             prescribed by their treating doctor.

         18. Has received Low Vision Rehab/Therapy within 30 days prior to Screening or intends to
             receive during the study

         19. Has an open sore(s) that may come in contact with the Valeda System, has periorbital
             skin erythema or is prone to such conditions with exposure to light.

         20. In the opinion of the Investigator, is unlikely to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clark Tedford</last_name>
    <phone>3605365119</phone>
    <email>ctedford@lumithera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy Croissant</last_name>
    <phone>8583971021</phone>
    <email>ccroissant@lumithera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Retina Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Kurokouchi</last_name>
      <phone>310-289-2478</phone>
      <phone_ext>3</phone_ext>
      <email>JKurokouchi@laretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Raquel Matsumoto</last_name>
      <email>RMatsumoto@laretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Boyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Greer</last_name>
      <phone>650-725-9184</phone>
      <email>lgreer7@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Yarp</last_name>
      <phone>1-650-497-5942</phone>
      <email>jyarp@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Do, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Eye Clinic</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Noemer</last_name>
      <phone>407-775-7495</phone>
      <email>jan.noemer@floridaeyeclinic.com</email>
    </contact>
    <investigator>
      <last_name>Samantha Xavier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21749</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Carson</last_name>
      <email>BrittanyC@retinacare.net</email>
    </contact>
    <contact_backup>
      <phone>(301) 665-1712</phone>
      <phone_ext>1025</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Allen Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Ear and Eye Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003-4284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katy Tai</last_name>
      <phone>212-979-4671</phone>
      <email>KTai@NYEE.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Tunik</last_name>
      <email>MTunik@nyee.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Rosen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Ventura</last_name>
      <phone>919-681-6585</phone>
      <email>alice.ventura@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lori Foraker</last_name>
      <phone>919-668-1859</phone>
      <email>loretta.foraker@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nora Lad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Chambersburg</city>
        <state>Pennsylvania</state>
        <zip>17201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee McGown</last_name>
      <phone>301-665-1712 ext. 1033</phone>
      <email>ReneeM@retinacare.net</email>
    </contact>
    <contact_backup>
      <last_name>Carson</last_name>
      <phone>301-665-1712 ext. 1025</phone>
      <email>BrittanyC@retinacare.net</email>
    </contact_backup>
    <investigator>
      <last_name>David Warrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Formoso</last_name>
      <email>Research@midatlanticretina.com</email>
    </contact>
    <investigator>
      <last_name>Allen C. Ho, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kameron Boren</last_name>
      <phone>936-273-6620</phone>
      <email>kameron.boren@houstonretina.com</email>
    </contact>
    <contact_backup>
      <last_name>Melisa Bocanegra</last_name>
      <phone>936-273-6620</phone>
      <email>melisa.bocanegra@houstonretina.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Eye Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yesenia Salinas, AA</last_name>
      <phone>956-631-8875</phone>
      <phone_ext>157</phone_ext>
      <email>ysalinas@vritx.com</email>
    </contact>
    <contact_backup>
      <last_name>Angelina Garza, BS</last_name>
      <phone>956-631-8875</phone>
      <phone_ext>118</phone_ext>
      <email>a_garza@vritx.com</email>
    </contact_backup>
    <investigator>
      <last_name>Victor Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Retina Center Northwest</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jillayne Newquist</last_name>
      <phone>360-307-0300</phone>
      <email>jillayne@retinacenternw.com</email>
    </contact>
    <investigator>
      <last_name>Todd Schneiderman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dry age-related macular degeneration</keyword>
  <keyword>Photobiomodulation</keyword>
  <keyword>Visual Acuity</keyword>
  <keyword>Contrast Sensitivity</keyword>
  <keyword>Drusen</keyword>
  <keyword>Optical coherence tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

